Head of Environment and Sustainability
About the job
- A minimum of 3 years of experience in the Health, Safety, and Environmental field.
- A bachelor's degree is required; Environmental Science or Engineering is the preferred major.
- Proficiency in environmental sustainability knowledge.
- Intermediate proficiency in product stewardship.
- High proficiency in management systems, regulatory knowledge, matrix management, problem solving, project management, striving for results, and the ability to influence.
- Direct and transversal management skills are desired.
- Strong ability to coach and facilitate initiatives that drive transformation and environmental performance.
- Ensure the site’s activities comply with all relevant environmental and sustainability regulations and standards at local, state, and company levels.
- Support the HSE Head in maintaining environmental permits.
- Serve as the primary point of contact with site-related environmental regulatory agencies and ensure timely submission of required reports and documentation.
- Develop and implement site plans aligned with Sanofi Environment and Sustainability Planet Care policies, including eco-design, climate change, waste circularity, water stewardship, and biodiversity.
- Conduct assessments and mitigate environmental impacts associated with site operations by identifying, assessing, and managing environmental impacts and opportunities.
- Monitor site environmental performance and oversee monitoring of environmental parameters, including air pollution, water and wastewater quality, waste management, and greenhouse gas emissions.
- Lead initiatives to reduce the site’s environmental footprint, including eco-design, water stewardship, waste, and biodiversity initiatives.
- Support the engineering team in optimizing resource use and reducing the site’s environmental footprint, including energy, PIE, and water-efficiency roadmaps.
- Foster continuous improvement and drive innovation in environmental practices and process improvements.
- Lead investigations into severe environmental impacts, incidents, and near misses to determine root causes and implement corrective actions to prevent recurrence.
- Promote a proactive HSE culture on environmental topics by developing and delivering environmental and sustainability training for employees and stakeholders.
- Engage external environmental experts, including consultants, academies, and laboratories, to ensure the site has the environmental capabilities required for its responsibilities.
- Monitor and report local environmental and sustainability performance and trends, including the culture maturity index, to the site leadership team and senior management to support data-driven decisions.
- Ensure the quality and timeliness of environmental data reporting.
- Lead and manage the Environment team, including hiring, training, coaching, capability development, and performance evaluation.
- Foster site-wide employee awareness of environmental and sustainability programs and own delivery of continuous-improvement initiatives and projects that make measurable progress toward Sanofi’s environmental goals.
- Perform additional Health, Safety, and Environment duties as assigned to support organizational HSE objectives and compliance requirements.
- Develop local environmental and sustainability policies and programs.
- Validate the site’s budget and strategic plan to allocate sufficient resources for environmental programs.
- Decide on sustainability initiatives and follow progress on environmental improvement projects and initiatives.
- Approve final reports and recommendations following safety incident investigations.
- Environmental Science or Engineering is the preferred major for the required bachelor's degree.
- Direct and transversal management skills are desired.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.
Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)